Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease

By afschroeder • March 25, 2026

Roney AR, Orr D, Barghi A, Hussani S, Cusumano V, Limketkai BN, Sauk JS. Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease. Dig Dis Sci. 2026 Mar 24. doi: 10.1007/s10620-026-09797-7. Epub ahead of print. PMID: 41874779.

Tags: Adverse events, Anti-tumor necrosis factor, Digestive Diseases, General Internal Medicine, inflammatory bowel disease, long-term, Publications, Resident, safety

Characterizing Abdominal Pain and Irritable Bowel Syndrome Among Individuals With Cirrhosis: Results of a Nationwide Survey

Deng LX, Almario CV, Lai JC, Spiegel BMR, Rubin JB. Characterizing Abdominal Pain and Irritable Bowel Syndrome Among Individuals With Cirrhosis: Results of a Nationwide[...]

Fraudulent and Imposter Participants in Qualitative Research: Experiences from Two Multi-Site Studies

Harden D, Rodriguez N, Roybal K, Coffin T, Johnson G, Le Beaux K, Connolly M, Rountree J, Ukaegbu C, Revette AC, Nava-Coulter B, Caruso A,[...]

Modulate Obesity and relateD metabolic complIcations For Yielding improvements in IBD outcomes (MODIFY-IBD): consensus on obesity and cardiometabolic comorbidities in inflammatory bowel disease using systematic reviews and the RAND/UCLA appropriateness method

Devi J, Samaan S, Sehgal P, Mohamed M, Vincent M, Coombs S, Doering M, Barnes EL, Johnson AM, Yarur AJ, Deepak P. Modulate Obesity and[...]